FDA issues no new psychedelic-specific guidance this quarter; agency communication stays limited to esketamine/ketamine labeling clarifications.

Predicted 2026-08-29 · Resolves 2026-11-28 · regulatory · USA

70%

ORACLE CONFIDENCE

⏳ Pending

Every outcome is scored publicly in the ledger.

The FDA (the US Food and Drug Administration, which decides what drugs are legal to prescribe) is not expected to publish any new rules or official guidance about classic psychedelics like psilocybin, LSD, or MDMA before late November 2026. The only updates on its radar are minor label tweaks for esketamine and ketamine, which are already approved. This matters because without new guidance, drug developers have no clearer roadmap for getting psychedelic medicines approved.

Resolution rule: YES if, by 2026-11-28, FDA has NOT published any new draft or final guidance document specifically addressing classic psychedelics (psilocybin, LSD, MDMA, etc.). Source: fda.gov guidance database and federalregister.gov. Check date: 2026-11-28. NO if any such psychedelic-specific guidance is posted.

No item in today's docket signals imminent draft or final psychedelic guidance; the pipeline is not mature enough for a policy document this quarter. Included as the single permitted baseline, not the top pick.

5 new falsifiable predictions, every day at 12:05 PM ET.

Get tomorrow's Oracle →